Understand vasomotor symptoms in relation to cardiometabolic risk and the role of hormone therapy in managing them.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I will walk you through a modern, evidence-based, and integrative approach to menopause, vasomotor symptoms, hot flashes, night sweats, menopausal hormone therapy, and nonhormonal treatment options. My goal is to make the science understandable while also explaining how clinical decisions are made in real patient care.

Menopause is not simply the end of menstrual cycles. It is a whole-body neuroendocrine transition involving the ovaries, brain, cardiovascular system, bones, skin, urogenital tissues, musculoskeletal system, metabolism, and autonomic nervous system. Many patients come in asking whether they will have hot flashes forever, whether hormone therapy is safe, and whether there are alternatives if they cannot or do not want to use hormones.

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, I integrate chiropractic care, functional medicine, rehabilitation, personal injury care, and women’s health support within a multidisciplinary model. I am honored to work with Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933, who brings more than 40 years of experience as an internist and serves as our Medical Director and Collaborative Physician. Her internal medicine expertise strengthens diagnostic safety, medication oversight, cardiovascular risk evaluation, and collaborative decision-making for patients considering hormone and nonhormonal therapies.

This post discusses the physiology of menopause, why estradiol decline, KNDy neurons, neurokinin B, and the hypothalamic thermoregulatory center matter, how transdermal estrogen, micronized progesterone, SSRIs/SNRIs, gabapentin, clonidine, fezolinetant, SERMs, local vaginal estrogen, and lifestyle strategies are used, and how integrative chiropractic care may support nervous system regulation, thoracic mechanics, sleep quality, pain reduction, and overall resilience.

Understanding Menopause and Vasomotor Symptoms From an Integrative Clinical Perspective

Many women arrive in my office feeling exhausted, frustrated, and unheard. A patient like “Miss Jenny,” a 52-year-old professional, may describe waking multiple times each night feeling as if she is trapped under a hot blanket. She may be drenched in sweat, chilled afterward, and unable to return to restorative sleep. During the day, she may experience sudden waves of heat, flushing, anxiety-like sensations, and brain fog.

The first thing I tell patients is this: you are not imagining it. Vasomotor symptoms, commonly known as hot flashes and night sweats, are real neuroendocrine events. They are not simply emotional reactions, nor signs of weakness. They reflect changes in ovarian hormone production, brain thermoregulation, autonomic signaling, vascular tone, and sleep physiology.

Menopause is clinically defined as the final menstrual period followed by 12 consecutive months without menstruation, assuming no other medical cause explains the absence of cycles. In the United States, the median age of natural menopause is approximately 52 years (Harlow et al., 2012; Santoro et al., 2021). However, the transition usually begins years earlier, often between ages 45 and 55.

Important terms include:

• Menopause: 12 months after the final menstrual period
• Perimenopause: the transition period leading up to menopause, often marked by cycle irregularity and symptoms
• Early menopause: menopause before age 45
• Premature menopause or primary ovarian insufficiency: menopause before age 40
• Late menopause: menopause after approximately age 54 or 55
• Postmenopause: the years after menopause has occurred

The menopausal transition affects far more than the reproductive system. It can influence:

• Sleep quality
• Mood regulation
• Cardiovascular risk
• Bone density
• Joint and connective tissue health
• Skin and collagen
• Genitourinary tissues
• Metabolic function
• Autonomic nervous system balance

This is why a multidisciplinary approach is so valuable.

Our El Paso Multidisciplinary Menopause and Integrative Care Model

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, our model is built around coordinated care. Menopause care often requires more than one perspective because symptoms may involve hormones, cardiovascular risk, sleep disruption, musculoskeletal pain, metabolic imbalance, stress physiology, and nervous system regulation.

Medical Direction With Dr. Maria Guadalupe Cardenas, MD

Dr. Maria Guadalupe Cardenas, MD, is Board Certified in Internal Medicine and has more than 40 years of experience as an internist. She serves as our Medical Director and Collaborative Physician.

Her credentials include:

• Name: Dr. Maria Guadalupe Cardenas, MD
• Board Certification: Internal Medicine
• NPI: #1164426749
• Texas MD License: #J2933
• Role: Medical Director and Collaborative Physician
• Practice: Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic
• Location: El Paso, Texas

Dr. Cardenas provides medical oversight for:

• Risk stratification
• Medication safety
• Cardiovascular and metabolic assessment
• Blood pressure management
• Diabetes and lipid evaluation
• Contraindication review for hormone therapy
• Collaborative decision-making for complex patients
• Coordination with specialists such as cardiology, oncology, gynecology, or neurology when needed

My Role as Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

My work combines several clinical lenses:

• Chiropractic biomechanics
• Family nurse practitioner evaluation
• Functional medicine
• Rehabilitation
• Personal injury care
• Nervous system regulation
• Musculoskeletal and postural assessment
• Lifestyle medicine
• Clinical education

Through my clinical observations and educational work shared through Chiropractic Scientist and my professional updates on LinkedIn, I continue to emphasize that menopause care must consider the whole person: hormones, spine, nervous system, metabolism, sleep, inflammation, injury history, and daily function.

Clinical observation resources:

• Chiropractic Scientist
• Alex Jimenez LinkedIn Profile

STRAW+10 Menopause Staging and Why It Matters Clinically

To help patients understand where they are in the menopausal journey, I use standardized staging concepts from the Stages of Reproductive Aging Workshop, commonly known as STRAW+10 (Harlow et al., 2012). These stages help clinicians interpret symptoms, menstrual changes, and expected hormonal variability.

Late Reproductive Stage

During this stage, menstrual cycles may still appear regular, but subtle changes can begin. Follicle quantity and quality decline, and follicle-stimulating hormone, or FSH, may become more variable.

Early Menopausal Transition

This stage often includes menstrual cycle variability of 7 days or more. A woman may notice that periods come early one month and late the next.

Late Menopausal Transition

This stage includes skipped cycles or intervals of 60 days or more without menstruation. FSH generally rises, but levels can still fluctuate significantly.

Early Postmenopause

This includes the first 1 to 2 years after menopause. Vasomotor symptoms often peak during this time.

Late Postmenopause

This occurs several years after menopause. Some women continue to experience hot flashes and night sweats for many years. Persistent symptoms are not unusual, and treatment can still be individualized.

The reason staging matters is that a 45-year-old with irregular cycles, a 52-year-old who has not had a period for 15 months, and a 62-year-old with new hot flashes require different diagnostic reasoning and risk assessment.

The Physiology of Hot Flashes and Night Sweats

Hot flashes are not simply episodes of feeling warm. They are hypothalamic thermoregulatory events involving the brain, blood vessels, sweat glands, sex hormones, neurotransmitters, and autonomic nervous system.

Estradiol Decline and Ovarian Aging

During reproductive years, the ovaries produce estradiol, the dominant and most biologically active estrogen. As ovarian follicles decline, inhibin production decreases. Inhibin normally helps regulate the pituitary gland. When inhibin drops, the pituitary releases more FSH.

However, during perimenopause, FSH can be unpredictable. It may be elevated one day and closer to normal another day. This is why routine FSH testing is often not necessary in a typical 52-year-old woman with classic menopausal symptoms and 12 months without menstruation.

Hormonal changes include:

• Inhibin decreases
• FSH rises and fluctuates
• Estradiol becomes erratic and later declines
• Progesterone declines as ovulation becomes inconsistent
• Estrone becomes relatively more prominent after menopause
• Testosterone gradually decreases with age
• DHEA and DHEAS vary between individuals

After menopause, the body still produces some estrogen, mainly estrone, through peripheral conversion in adipose and adrenal-related tissues. However, total estrogen tone is much lower than during the reproductive years (Santoro et al., 2021).

The Thermoneutral Zone and the Hypothalamus

The hypothalamus is the brain’s central thermostat. It maintains the body’s temperature within a comfortable range called the thermoneutral zone.

When estrogen levels decline, this thermoneutral zone narrows. That means even a tiny increase in core temperature can trigger a dramatic heat-loss response.

The body responds with:

• Peripheral vasodilation
• Sweating
• Flushing
• Increased heart rate
• Autonomic activation
• Post-flush chills

This explains why a woman may suddenly feel intense heat even when the room temperature has not changed.

KNDy Neurons, Neurokinin B, and Modern Menopause Research

One of the most important modern discoveries in menopause science involves KNDy neurons. These hypothalamic neurons produce:

• Kisspeptin
• Neurokinin B
• Dynorphin

These neurons help regulate reproductive hormone signaling and thermoregulation. Estrogen normally restrains neurokinin B signaling. When estrogen declines, neurokinin B activity becomes more prominent, increasing KNDy neuron activation and contributing to hot flashes (Mittelman-Smith et al., 2012; Rance et al., 2013).

This research helps explain why newer medications such as neurokinin-3 receptor antagonists, including fezolinetant, can reduce hot flashes without giving estrogen. These medications target the pathway involved in thermoregulatory instability (Lederman et al., 2023).

LH Pulses and Hot Flashes

Hot flashes are often associated with luteinizing hormone, or LH, pulses. LH itself is not the direct cause of hot flashes, but LH pulsatility reflects shared hypothalamic activity involved in both reproductive signaling and thermoregulation (Freedman, 2005).

How I Diagnose Menopause and Vasomotor Symptoms

For a typical patient around age 52 who has gone more than 12 months without a menstrual period and has classic hot flashes and night sweats, the diagnosis is usually clinical. Routine hormone testing is not always necessary because FSH and estradiol fluctuate during the transition.

When Testing May Be Helpful

Testing may be considered when:

• Menopause occurs before age 45
• Symptoms occur before age 40
• Pregnancy must be excluded
• Thyroid disease is suspected
• Infection, malignancy, or medication effects are possible
• Autonomic disorders are suspected
• Symptoms are atypical
• A patient strongly prefers more data after understanding the limitations

Clinical Evaluation Includes

A thorough evaluation may include:

• Menstrual history
• Symptom pattern
• Sleep assessment
• Medication review
• Breast cancer and family history
• Cardiovascular risk assessment
• Blood pressure
• Weight and waist circumference
• Metabolic labs when appropriate
• Thyroid evaluation
• Pelvic evaluation when GSM or bleeding is present
• Musculoskeletal and postural assessment
• Cervical-thoracic mobility evaluation
• Pain and injury history

The goal is not to order unnecessary tests. The goal is to understand the patient’s full risk profile and symptom drivers.

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

Menopausal Hormone Therapy for Hot Flashes and Night Sweats

Menopausal hormone therapy, or MHT, remains the most effective treatment for moderate to severe vasomotor symptoms in appropriate candidates (The NAMS 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Hormone therapy may be used for:

• Moderate to severe hot flashes
• Night sweats
• Sleep disruption related to vasomotor symptoms
• Genitourinary syndrome of menopause
• Prevention of bone loss
• Premature menopause or primary ovarian insufficiency
• Surgical menopause when appropriate

Why Estrogen Helps

Estrogen helps widen the narrowed thermoneutral zone. In practical terms, it makes the hypothalamic thermostat less reactive. This reduces the frequency and intensity of hot flashes.

Estrogen also supports:

• Vaginal and urethral tissue health
• Bone density
• Skin and collagen integrity
• Sleep quality in some patients
• Joint and connective tissue function
• Mood stability in selected patients

Estrogen Alone Versus Estrogen Plus Progestogen

This point is critical:

• If a woman does not have a uterus, estrogen therapy alone may be used.
• If a woman has a uterus, estrogen must be paired with a progestogen to protect the endometrium.

Unopposed estrogen can stimulate the uterine lining and increase the risk of endometrial hyperplasia and endometrial cancer. This is why progesterone protection is not optional for women with a uterus.

Common endometrial protection options include:

• Oral micronized progesterone
• Synthetic progestins
• Combination estrogen-progestin patches
• Levonorgestrel intrauterine systems in selected cases

Why Transdermal Estrogen Is Often Preferred

In many patients, I prefer discussing transdermal estradiol first. Transdermal therapy includes patches, gels, sprays, and lotions that deliver estradiol through the skin.

Benefits of Transdermal Estrogen

Transdermal estrogen bypasses first-pass liver metabolism. This matters because oral estrogen passes through the liver first and can increase clotting factors, triglycerides, and inflammatory markers in some patients.

Potential advantages of transdermal estrogen include:

• Lower risk of venous thromboembolism compared with oral estrogen
• More stable blood levels
• Less hepatic stimulation
• Less impact on triglycerides
• Practical dosing flexibility
• Strong symptom relief for many patients

This is especially important for patients with:

• Cardiovascular risk factors
• Hyperlipidemia
• Diabetes
• Migraine concerns
• History of clotting risk requiring careful evaluation
• Preference for steady symptom control

Common Transdermal Options

Options include:

• Estradiol patches
• Generic estradiol patches
• Vivelle-Dot
• Climara
• Minivelle
• Estradiol gels
• EstroGel
• Divigel
• Estradiol sprays
• EvaMist
• Estradiol lotions or topical preparations

Dosing is individualized. I generally believe in starting with the lowest effective dose and titrating based on symptom relief and tolerability.

Patients using gels, sprays, or lotions should allow the medication to dry completely before dressing and should avoid skin-to-skin transfer to others.

Oral Hormone Therapy and Combination Products

Some patients prefer oral therapy or cannot tolerate patches or gels. Oral therapy may still be appropriate for selected patients after risk assessment.

Oral Estrogen-Only Therapy

Oral estrogen-only therapy is used only in women without a uterus.

Examples include:

• Conjugated equine estrogens
• Premarin
• Oral estradiol
• Synthetic or plant-derived estrogen options

The key concern is that oral estrogen is associated with a higher risk of clotting than transdermal estrogen due to hepatic first-pass metabolism.

Oral Estrogen Plus Progestin Therapy

Women with a uterus require endometrial protection. Combination options may include:

• Prempro
• Estradiol plus norethindrone acetate
• Estradiol plus drospirenone
• Estradiol with separate micronized progesterone

The choice of progestogen matters. Some patients experience mood changes, bloating, or breast tenderness with one formulation but not another. Micronized progesterone is often favored because it may be better tolerated and may support sleep in some patients.

SERMs, Duavee, and Specialized Hormone Options

A selective estrogen receptor modulator, or SERM, acts like estrogen in some tissues and blocks estrogen effects in others.

One specialized option is conjugated estrogens plus bazedoxifene, marketed as Duavee.

Why Bazedoxifene Is Used

Bazedoxifene helps protect the endometrium without requiring a traditional progestin. This can be useful for selected women who need vasomotor symptom relief and bone support but do not tolerate progestins well.

Potential benefits include:

• Relief of vasomotor symptoms
• Endometrial protection
• Bone protection
• Improvement in vulvovaginal atrophy
• Possible reduction in breast density

This is not for everyone, but it is part of the modern individualized treatment landscape.

Injectable Estradiol

Injectable estradiol, such as estradiol valerate or estradiol cypionate, is generally reserved for severe refractory symptoms or other specialized clinical contexts. These options require careful dosing, monitoring, and endometrial protection if the uterus is present.

Nonhormonal Treatments for Menopause Hot Flashes

Not every woman can or wants to use hormone therapy. Some have contraindications. Others prefer to avoid hormones. Fortunately, evidence-based nonhormonal options exist.

SSRIs and SNRIs

Medications such as paroxetine, venlafaxine, and desvenlafaxine can reduce hot flash frequency and severity by influencing serotonergic and noradrenergic pathways involved in hypothalamic thermoregulation (Freeman et al., 2011; The NAMS 2023 Nonhormone Therapy Position Statement Advisory Panel, 2023).

These may be useful for patients who also have:

• Anxiety symptoms
• Mood changes
• Sleep disruption
• Contraindications to estrogen
• Preference for nonhormonal care

Gabapentin

Gabapentin can be especially helpful when night sweats disrupt sleep. It may reduce central neuronal excitability and improve sleep continuity in selected patients.

Clonidine

Clonidine may provide modest benefit but can be limited by side effects such as:

• Dry mouth
• Low blood pressure
• Dizziness
• Fatigue

Fezolinetant and NK3 Receptor Antagonists

Fezolinetant is a newer nonhormonal therapy that targets the neurokinin-3 receptor. It works directly on the neurokinin B pathway involved in KNDy neuron thermoregulatory signaling (Lederman et al., 2023).

This is a major development because it addresses the hot flash mechanism without estrogen exposure. Monitoring liver function and reviewing medications are important according to prescribing guidance.

Genitourinary Syndrome of Menopause and Local Therapy

Genitourinary syndrome of menopause, or GSM, includes:

• Vaginal dryness
• Burning
• Irritation
• Painful intercourse
• Urinary urgency
• Recurrent urinary tract infections
• Urethral discomfort
• Overactive bladder symptoms

If GSM is the only concern, local vaginal therapy is often preferred over systemic hormone therapy.

Options include:

• Low-dose vaginal estrogen cream
• Vaginal estrogen tablets
• Vaginal estrogen rings
• Vaginal DHEA
• Ospemifene

Local estrogen has minimal systemic absorption for many patients and can be very effective. In patients with a history of breast cancer or estrogen-sensitive cancer, I do not make that decision alone. Collaboration with the patient’s oncologist is essential.

Contraindications and Safety Considerations for Hormone Therapy

Hormone therapy can be powerful and helpful, but it must be used thoughtfully.

Important Contraindications or High-Risk Situations

Systemic hormone therapy is generally avoided or requires specialist collaboration in patients with:

• Current or past estrogen-sensitive cancer
• Unexplained postmenopausal vaginal bleeding
• Active liver disease
• Recent stroke
• Recent myocardial infarction
• High-risk thrombophilia
• Active or recent arterial thrombotic disease
• Uncontrolled hypertension
• Complex cardiovascular disease
• Certain migraine with aura scenarios requiring careful evaluation

Postmenopausal Bleeding Requires Evaluation

Any unexplained postmenopausal bleeding requires attention. Evaluation may include:

• Pelvic exam
• Transvaginal ultrasound
• Endometrial stripe measurement
• Endometrial biopsy if indicated

This is one reason medical oversight from Dr. Cardenas is so valuable. Safety is built into the model.

Side Effects and Follow-Up During Menopause Treatment

When starting MHT, the body may need time to adjust.

Common early side effects may include:

• Breast tenderness
• Spotting or bleeding
• Bloating
• Fluid retention
• Headaches
• Mood changes
• Temporary hair shedding in some cases

If symptoms are persistent or severe, we reassess the dose, route, and formulation. Sometimes lowering the dose, changing the progestogen, switching from oral to transdermal therapy, or adding local GSM therapy solves the problem.

Follow-up often includes:

• Symptom diary review
• Blood pressure monitoring
• Weight and metabolic assessment
• Breast health screening
• Pelvic exam when indicated
• Mammography according to guidelines
• Bone density evaluation when appropriate
• Medication side effect review
• Annual reassessment
• Dose tapering when appropriate

The goal is not to place every patient on therapy indefinitely. The goal is to use the right tool for the right patient at the right time.

Lifestyle Medicine for Menopause Symptom Control

Lifestyle strategies are not a replacement for needed medical care, but they are foundational. A reactive nervous system, poor sleep, inflammation, blood sugar instability, alcohol use, and stress can worsen vasomotor symptoms.

Sleep Optimization

Sleep is often the first domino. Repeated night sweats fragment sleep, and poor sleep makes the nervous system more reactive.

Helpful strategies include:

• Cool bedroom temperature
• Breathable bedding
• Moisture-wicking sleepwear
• Consistent sleep and wake times
• Avoiding alcohol near bedtime
• Reducing late caffeine
• Cognitive behavioral therapy for insomnia when needed

Nutrition and Metabolic Stability

I often focus on:

• Whole foods
• Adequate protein
• Omega-3-rich foods
• Fiber intake
• Blood sugar stability
• Reduced refined sugar
• Hydration
• Alcohol reduction
• Caffeine timing

Insulin resistance, inflammation, and unstable blood sugar can increase sympathetic activation and worsen sleep.

Exercise and Bone Health

Exercise supports:

• Bone density
• Muscle mass
• Mood
• Insulin sensitivity
• Cardiovascular health
• Joint function
• Sleep regulation

A balanced program includes:

• Resistance training
• Aerobic conditioning
• Mobility work
• Balance training
• Postural strengthening

Integrative Chiropractic Care for Menopause, Nervous System Regulation, and Musculoskeletal Health

Chiropractic care does not replace hormone therapy or medical evaluation. Instead, it can complement menopause care by addressing the musculoskeletal and nervous system factors that influence symptom burden.

Why the Cervical-Thoracic Region Matters

Many patients with hot flashes describe chest tightness, neck tension, shallow breathing, and a sense of internal pressure during episodes. In clinical practice, I often observe that cervicothoracic restriction, forward head posture, upper thoracic stiffness, and rib cage dysfunction may amplify distress during hot flashes.

The upper thoracic spine and rib cage influence:

• Breathing mechanics
• Diaphragm function
• Sympathetic tone
• Chest wall expansion
• Postural load
• Neck and shoulder tension
• Perceived ease of cooling down after a flash

Chiropractic and Rehabilitation Techniques Used

Care may include:

• Gentle cervical and thoracic mobilization
• Thoracic extension work
• Rib mobility techniques
• Diaphragmatic breathing training
• Scapular stabilization
• Postural correction
• Myofascial release
• Sensorimotor retraining
• Progressive strengthening
• Mobility restoration after injury

Why These Techniques May Help

The reasoning is physiological and functional:

• Improved thoracic motion supports deeper breathing.
• Better rib cage mechanics may reduce panic-like sensations during heat episodes.
• Reduced neck and upper back tension may lower sympathetic arousal.
• Improved posture reduces muscular strain.
• Diaphragmatic breathing supports parasympathetic activation.
• Pain reduction improves sleep quality.
• Better sleep reduces nervous system reactivity.

In my clinical observations, patients who combine appropriate medical therapy with thoracic mobility, breathing retraining, and rehabilitation often report fewer nocturnal awakenings, improved recovery after flashes, and less distress during episodes.

Personal Injury, Chronic Pain, and Menopause Symptoms

Menopause symptoms can feel worse when a patient is also dealing with chronic pain, whiplash, spinal injury, occupational strain, or post-traumatic musculoskeletal dysfunction.

Chronic pain increases:

• Sympathetic tone
• Cortisol burden
• Sleep fragmentation
• Inflammatory signaling
• Muscle guarding
• Emotional distress

All of these can worsen the experience of hot flashes and night sweats.

In our personal injury and rehabilitation setting, we may address:

• Whiplash-related cervical dysfunction
• Upper thoracic stiffness
• Shoulder girdle compensation
• Low back and pelvic mechanics
• Balance and gait changes
• Chronic pain-related sleep disruption
• Work-related postural overload

By reducing pain-mediated arousal, patients often regain a wider functional comfort window. That means the nervous system becomes less reactive, sleep improves, and menopause symptoms become easier to manage.

A Practical Menopause Care Pathway for a Patient Like Miss Jenny

For a 52-year-old patient who has not had a menstrual period for 15 months and is experiencing debilitating night sweats, my approach is stepwise.

Step 1: Explain the Physiology

I explain that symptoms are likely related to:

• Reduced estradiol
• Narrowed thermoneutral zone
• KNDy neuron activation
• Neurokinin B signaling
• Autonomic nervous system surges
• Sleep fragmentation

Step 2: Assess Risk

We review:

• Personal cancer history
• Family breast cancer history
• Blood clot history
• Stroke or heart disease history
• Migraine history
• Blood pressure
• Liver function concerns
• Medications
• Uterus status
• Bleeding history

Step 3: Discuss Treatment Options

If she is medically appropriate and wants hormone therapy, we may consider:

• Transdermal estradiol
• Micronized progesterone if uterus is present
• Follow-up in 6 to 8 weeks

If she cannot or does not want hormone therapy, we may consider:

• Paroxetine
• Venlafaxine
• Desvenlafaxine
• Gabapentin
• Fezolinetant
• Clonidine in selected cases

If GSM is present, we may add:

• Local vaginal estrogen
• Vaginal DHEA
• Ospemifene when appropriate

Step 4: Add Integrative Support

We include:

• Sleep cooling strategies
• Nutrition and blood sugar stabilization
• Exercise prescription
• Thoracic mobility care
• Breathing retraining
• Postural rehabilitation
• Stress regulation
• Pain reduction strategies

Step 5: Monitor and Adjust

We track:

• Hot flash frequency
• Night sweat severity
• Sleep quality
• Mood
• Blood pressure
• Side effects
• Functional improvement
• GSM response
• Pain and mobility changes

This is how care becomes personalized rather than generic.

Clinical Pearls From My Integrative Menopause Practice

Here are key principles I use when guiding patients:

• Treat sleep early because a tired nervous system is more reactive.
• Use shared decision-making because patient values matter.
• Consider transdermal estrogen when risk factors make oral estrogen less desirable.
• Always protect the endometrium in women with a uterus.
• Do not ignore GSM because vaginal and urinary symptoms can persist even when hot flashes improve.
• Use symptom diaries to guide treatment instead of guessing.
• Address pain and posture because musculoskeletal stress can amplify autonomic symptoms.
• Collaborate medically when hypertension, diabetes, cardiovascular disease, cancer history, liver disease, or clotting risk is present.
• Start low and adjust carefully because the goal is symptom relief with the lowest effective intervention.
• Integrate rehabilitation and breathing, as the nervous system, spine, rib cage, and diaphragm influence how the body experiences stress and heat.

Key Takeaways for Evidence-Based Menopause Relief

Menopause is a normal biological transition, but severe symptoms deserve compassionate and evidence-based care. Hot flashes and night sweats are driven by changes in estrogen signaling, hypothalamic thermoregulation, KNDy neuron activity, neurokinin B pathways, vascular responses, and autonomic nervous system activation.

For eligible patients, menopausal hormone therapy remains the most effective treatment for moderate to severe vasomotor symptoms. Transdermal estradiol is often favored because it avoids first-pass hepatic metabolism and may carry a lower risk of clotting than oral estrogen. Women with a uterus require progestogen protection, often with micronized progesterone.

For patients who cannot or do not want hormones, SSRIs, SNRIs, gabapentin, clonidine, and fezolinetant provide important nonhormonal pathways. For GSM, local vaginal estrogen, DHEA, and other targeted therapies can be life-changing.

In our El Paso multidisciplinary model, Dr. Maria Guadalupe Cardenas, MD, provides internal medicine leadership and safety oversight. At the same time, I integrate chiropractic biomechanics, functional medicine, rehabilitation, personal injury care, and nervous system support. Together, we aim to help patients move through menopause with clarity, safety, dignity, and improved quality of life.

References

• STRAW+10 Executive Summary: Addressing the Unfinished Agenda of Staging Reproductive Aging
  • Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). STRAW+10: Addressing the unfinished agenda of staging reproductive aging. Human Reproduction, 27(10), 2844-2851. https://doi.org/10.1093/humrep/des139
• The Menopausal Transition
  • Santoro, N., Roeca, C., Peters, B. A., & Neal-Perry, G. (2021). The menopausal transition. The New England Journal of Medicine, 385(16), 1576-1587. https://doi.org/10.1056/NEJMra1914769
• Physiology of Hot Flashes
  • Freedman, R. R. (2005). Physiology of hot flashes. Menopause, 12(6), 567-572. https://doi.org/10.1097/01.gme.0000181515.51192.10
• Role of KNDy Neurons in Estrogen Modulation of the GnRH Pulse Generator and Thermoregulation
  • Mittelman-Smith, M. A., Williams, H., Krajewski-Hall, S. J., McMullen, N. T., & Rance, N. E. (2012). Role for kisspeptin/neurokinin B/dynorphin neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Endocrinology, 153(5), 1973-1985. https://doi.org/10.1210/en.2011-1902
• Neurokinin B and the Hypothalamic Regulation of Reproduction and Thermoregulation
  • Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: A novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211-227. https://doi.org/10.1016/j.yfrne.2013.05.002
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society
  • The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
• The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society
  • The NAMS 2023 Nonhormone Therapy Position Statement Advisory Panel. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590. https://doi.org/10.1097/GME.0000000000002200
• Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
  • Lederman, S. A., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., English, M., Franklin, C., & Neal-Perry, G. (2023). Fezolinetant for treatment of moderate to severe vasomotor symptoms associated with menopause: A randomized clinical trial. JAMA, 330(6), 566-575. https://doi.org/10.1001/jama.2023.13592
• Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women
  • Freeman, E. W., Guthrie, K. A., Caan, B., Sternfeld, B., Cohen, L. S., Joffe, H., Carpenter, J. S., Anderson, G. L., Larson, J. C., Ensrud, K. E., Reed, S. D., Newton, K. M., Sherman, S., Sammel, M. D., & LaCroix, A. Z. (2011). Efficacy of escitalopram for hot flashes in healthy menopausal women: A randomized controlled trial. JAMA, 305(3), 267-274. https://doi.org/10.1001/jama.2010.2016
• Vasomotor Symptoms and Menopause: Findings From the Study of Women’s Health Across the Nation
  • Thurston, R. C., & Joffe, H. (2021). Vasomotor symptoms and menopause: Findings from the Study of Women’s Health Across the Nation. Obstetrics and Gynecology Clinics of North America, 48(4), 725-740. https://doi.org/10.1016/j.ogc.2021.07.006
• Vasomotor Symptoms and Cardiometabolic Risk
  • Thurston, R. C., & Joffe, H. (2011). Vasomotor symptoms and menopause: Findings from the Study of Women’s Health Across the Nation. Menopause, 18(6), 603-612. https://doi.org/10.1097/gme.0b013e318206b1ba
• Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
  • Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. https://doi.org/10.1210/jc.2015-2236
• Management of Menopausal Symptoms
  • Kaunitz, A. M., & Manson, J. E. (2015). Management of menopausal symptoms. Obstetrics & Gynecology, 126(4), 859-876. https://doi.org/10.1097/AOG.0000000000001058
• Use of Hormone Replacement Therapy and Risk of Venous Thromboembolism
  • Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2020). Use of hormone replacement therapy and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. BMJ, 371, m3873. https://doi.org/10.1136/bmj.m3873
• Managing Vasomotor Symptoms in Women After Breast Cancer
  • Pinkerton, J. V., & Santen, R. J. (2019). Managing vasomotor symptoms in women after breast cancer. Climacteric, 22(6), 544-552. https://doi.org/10.1080/13697137.2019.1601438

SEO Tags: menopause, vasomotor symptoms, hot flashes treatment, night sweats menopause, menopausal hormone therapy, MHT, HRT, transdermal estradiol, micronized progesterone, fezolinetant, NK3 receptor antagonist, KNDy neurons, neurokinin B, genitourinary syndrome of menopause, vaginal estrogen, menopause and chiropractic care, integrative chiropractic care, functional medicine menopause, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso menopause care, internal medicine collaborative care, personal injury rehabilitation, thoracic mobility, autonomic nervous system, menopause sleep support, osteoporosis prevention, SERMs, Duavee, SSRIs for hot flashes, gabapentin menopause, women’s health El Paso